Superworth

RadNet price to free cash flow RDNT

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
76.5×
10-year median
24.5×
Against its 10-year history
83rd
percentile: 0 is its lowest day, 100 its highest
10-year range
6.1× to 170×
Peer median
26.4×

RadNet's price to free cash flow is 76.5× as of Oct 23, 2026.

That is above its ten-year median of 24.5×, higher than on 83% of days in the last ten years.

Over that time it ranged from 6.1× in Dec 2018 to 170× in Aug 2024.

The median for 10 diagnostics and research stocks of a similar size is 26.4×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far76.5×40.4×116×
2025108×43.6×123×
202456.0×56.0×170×
202383.7×40.0×87.5×
202291.9×21.9×110×
202127.6×8.0×28.8×
20209.3×7.2×35.2×
201929.7×6.2×29.7×
20186.1×6.1×11.3×
20179.2×8.2×19.0×
201611.8×7.5×14.0×
201513.9×7.3×25.0×
201426.7×4.6×38.7×
20135.0×2.8×7.5×
20122.7×2.6×6.9×

Against its peers

Companies in Medical - Diagnostics & Research nearest RadNet's size, closest first, today.

CompanyPrice to free cash flow
RDNTRadNet76.5×
BLLNBillionToOne153×
LNTHLantheus16.8×
VCYTVeracyte23.2×
CDNACareDxn/m
CAICaris Life Sciences73.0×
BIOBio-Rad Laboratories28.0×
RVTYRevvity31.7×
MEDPMedpace26.4×
LHLabcorp23.1×
DGXQuest Diagnostics19.8×
Peer median26.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on RadNet

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.